Search results
Bristol-Myers (BMY) to Post Q2 Earnings: What is in the Cards?
Zacks via Yahoo Finance· 2 years agoInvestors will likely focus on the demand for Eliquis and Opdivo along with incremental contribution...
Will Eliquis, Opdivo Fuel Bristol-Myers (BMY) Q3 Earnings?
Zacks via Yahoo Finance· 2 years agoInvestors are likely to focus on the demand for Eliquis and Opdivo along with an incremental...
Q3 2023 Bristol-Myers Squibb Co Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 7 months agoParticipants Adam Lenkowsky; Executive VP, Chief Commercialization Officer & Head of U.S. Oncology; Bristol-Myers Squibb Company Christopher S. Boerner; Executive VP, COO & Director; Bristol-Myers ...
What's the most expensive property sold in RI? Feb. 3 real estate transactions
The Providence Journal via Yahoo News· 3 months agoTwo properties were sold for more than $2,000,000 each: A single-family home in Narragansett sold...
Housing Court in Barnstable: What to expect if you have to go
Cape Cod Times via Yahoo News· 7 months agoBARNSTABLE — Fighting foreclosure in housing court, a Centerville man told a judge he and another...
Analysts on Wall Street Lower Ratings for These 10 Stocks
Insider Monkey via Yahoo Finance· 2 months agoIn this article, we will discuss the 10 stocks recently downgraded by analysts. If you want to see...
The Most Energy-Efficient Manufacturing Plants of 2023
IEN via Yahoo Finance· 2 months agoLast week, the EPA recognized the 103 U.S. factories to earn Energy Star certification in 2023. The...
Seeing is believing: New Bedford walking tour shows where offshore wind jobs will be
The Standard-Times via Yahoo News· 2 years agoNEW BEDFORD — Community activist John "Buddy" Andrade understands why many have been skeptical about...
‘Live From My Den’ Season 4 Showcases a Diverse Lineup of Today’s Most Innovative Artists
Variety via Yahoo News· 1 year agoArtists Den brings “Live From My Den” back for another season, highlighting today’s most...
2 Biotech Stocks That Could Soar in the Third Quarter
Motley Fool· 2 years agoCould a lousy, no-good, rotten year for biotech have a silver lining? It's hard to imagine the market's sentiment about innovative drugmakers getting worse than it already is. The Nasdaq Biotechnology ...
